Multimer Detection System-Oligomerized Amyloid Beta (MDS-OA β ): A Plasma-Based Biomarker Differentiates Alzheimer's Disease from Other Etiologies of Dementia.

With emerging amyloid therapies, documentation of the patient's amyloid status to confirm the etiology of a clinical diagnosis is warranted prior to instituting amyloid-based therapy. The Multimer Detection System-Oligomeric Amyloid- β (MDS-OA β ) is a noninvasive blood-based biomarker utilized to measure A β oligomerization tendency. We determined the difference in MDS-OA β ratio across the groups: (a) no cognitive impairment or subjective cognitive impairment (NCI/SCI), (b) Alzheimer's disease (AD), (c) non-AD, and (d) mixed Alzheimer's disease-Vascular dementia (AD-VaD). MDS-OA β level was not significantly different between AD and mixed AD-VaD, but both groups were significantly different from the NCI/SCI and from the non-AD group. An MDS-OA β level of >1 could potentially indicate clinical variants of AD or mixed pathology (AD-VaD).